Government
Netherlands Enterprise Agency grants through a financial loan (“Innovatiekrediet”) €2.7 million for the development of a diagnostic skin cancer test.
It looks to be a pretty busy week for the U.S. Food and Drug Administration (FDA), with a number of target action dates for various drugs. Some were delayed, and some were already approved, but there are still a number on the schedule. Here’s a look.
The DEA has reclassified GW Pharmaceutical’s cannabidiol epilepsy treatment Epidiolex as a Schedule V product, which will clear the way for commercialization within the next six weeks.
The Trump administration has launched a sweeping federal review on the use of fetal tissue that includes the cancellation of a contract between a supplier and researchers at the U.S. Food and Drug Administration.
Politicians might deny climate change, but disease-carrying insects and their pathogens aren’t—they’re exploiting it.
Making the jump from biotech to politics may not seem like a typical career progression. So, what is driving these executives into politics?
Recently, a few companies and government programs have decided to enact their own plans that they believe will help bring down the cost of new therapies. Pharmaceutical companies have begun asserting their positions on the topic.
Epizyme, an innovative epigenetic therapy development company, announced this morning that the U.S. Food and Drug Administration has removed their former partial clinical hold reported in April of this year.
Palantir Technologies announced today that it has been awarded a three-year, $7 million contract by the National Institutes of Health (NIH).
Following AbbVie Lawsuit, Government Scrutinizes Industry-Provided Drug Educational Support Services
A federal investigation is underway into whether or not the nursing and other medical services provided by some pharmaceutical companies to doctor’s offices actually violate the law due to serving an illegal commercial service.
PRESS RELEASES